• PSS6 COST-EFFECTIVENESS OF INTERMITTENT VS. CONTINUOUS ANTI-TNF ALPHA THERAPY IN PLAQUE PSORIASIS

    May 1, 2008, 00:00

  • PDB1 EXENATIDE UTILIZATION AND EFFECTIVENESS IN A HEALTH PLAN POPULATION

    May 1, 2008, 00:00

  • PDB75 PRESCRIBING PATTERN AND PREDICTORS ASSOCIATED WITH THE USE OF HYPOGLYCAEMIC DRUGS- A CROSS-SECTIONAL STUDY IN ITALIAN GENERAL PRACTICE

    May 1, 2008, 00:00

  • PIH18 ASSESSING THE ASSOCIATION BETWEEN SCORE DIFFERENCES ON THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY (PMSIS) AND HEALTH-RELATED QUALITY OF LIFE

    May 1, 2008, 00:00

  • PCV96 THE EFFECT OF MEASUREMENT ERROR FROM POINT-OF-CARE INR DEVICES ON WARFARIN DOSING DECISIONS

    May 1, 2008, 00:00

  • PCN62 LEUPROLIDE ACETATE PERSISTENCE VARIES BY AGE IN PATIENTS WITH PROSTATE CANCER

    May 1, 2008, 00:00

  • PCN71 SOCIETAL PREFERENCES (UTILITIES) FORADVANCED MELANOMA HEALTH STATES IN THE UNITED KINGDOM (UK) AND AUSTRALIA

    May 1, 2008, 00:00

  • PIN23 PHARMACOECONOMIC ANALYSIS OF ANTIFUNGAL AGENTS FOR THE MANAGEMENT OF NON NEUTROPENIC PATIENTS WITH INVASIVE CANDIDIASIS ATTHE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)

    May 1, 2008, 00:00

  • PMC36 THE USE OF A MOBILE PHONE FOR ASSESSING MOOD AND PERFORMANCE IN EVERYDAY LIFE

    May 1, 2008, 00:00

  • PCV35 GADOFOSVESET IN THE MANAGEMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN CANADA-A MODEL APPROACH FOCUSING ON DIAGNOSTIC CONFIDENCE

    May 1, 2008, 00:00

  • PND18 HIGHER INPATIENT COSTS AMONG PATIENTS WITH SUBARACHNOID HEMORRHAGE COMPLICATED BY VASOSPASM

    May 1, 2008, 00:00

  • PRS4 PROGNOSTIC FACTORS OF PATIENTS TRANSFERRED TO CHRONIC RESPIRATORY CARE WARD

    May 1, 2008, 00:00

  • PRS23 PARTICIPANTS EXPERIENCE OF ASTHMA- RESULTS FROM A FOCUS GROUP STUDY

    May 1, 2008, 00:00

  • MD5 HEALTH CARE UTILIZATION BY MEDICARE ADVANTAGE BENEFICIARIES IN THE ERA OFTHE MEDICARE PART D DRUG BENEFIT COVERAGE GAP

    May 1, 2008, 00:00

  • PMH62 ASSESSING THE VALIDITY OF DERIVING CLINICAL DEMENTIA RATING (CDR) GLOBAL SCORES FROM INDEPENDENTLY OBTAINED FUNCTIONAL RATING SCALE (FRS) SCORES IN VASCULAR DEMENTIA AND MIXED VASCULAR DEMENTIA PATIENTS

    May 1, 2008, 00:00

  • PRS31 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON CHILD AND CAREGIVER PRODUCTIVITY

    May 1, 2008, 00:00

  • PIN28 A REALISTIC-AGE-STRUCTURED, DETERMINISTIC, COMPARTMENTAL. TRANSMISSION MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF VACCINATION AGAINST SEASONAL INFLUENZA

    May 1, 2008, 00:00

  • PDB69 COMPARISON OF HEALTH CARE UTILIZATION AND COSTS IN TYPE 2 DIABETES PATIENTS INITIATING ANALOG AND HUMAN INSULINS

    May 1, 2008, 00:00

  • PM4 EVALUATION OF ATHEORY OF GLOBAL HEALTH PREFERENCE FORMATION

    May 1, 2008, 00:00

  • PMC50 EVIDENCE ANDVALUE- IMPACT ON DECISION MAKING-THE EVIDEM FRAMEWORK AND POTENTIAL APPLICATIONS

    May 1, 2008, 00:00

  • PCV94 PREDICTING HIGH COSTS IN MEDICARE BENEFICIARIES WITH HEART FAILURE

    May 1, 2008, 00:00

  • DB2 COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY IN MEXICO

    May 1, 2008, 00:00

  • PMH40 TREATMENT COST AND COMORBIDITIES ASSOCIATED WITH OBESITY AMONG MEDICAID PATIENTS WITH BIPOLAR DISORDER

    May 1, 2008, 00:00

  • CN1 TRENDS IN TREATMENT AMONG ELDERLY COLORECTAL CANCER PATIENTS IN THE US- EVIDENCE FROM LINKED SEER-MEDICARE DATA

    May 1, 2008, 00:00

  • AC3 DEPRESSIVE SYMPTOMATOLOGY, MEDICATION PERSISTENCE, AND ASSOCIATED HEALTH CARE COSTS IN OLDER ADULTSWITH INSOMNIA

    May 1, 2008, 00:00

  • PND34 ASSOCIATION BETWEEN CHANGE IN OVERALL QUALITY OF LIFE (QOL), DISEASE LEVEL AND FUNCTIONAL STATUS SINCE NATALIZUMAB INITIATION

    May 1, 2008, 00:00

  • PRS13 PEDIATRIC ASTHMA- AN EMPLOYER PERSPECTIVE ON ANNUAL EMPLOYEE AND DEPENDENT COSTS FOR MEDICAL CARE AND PRESCRIPTION DRUGS

    May 1, 2008, 00:00

  • PMH86 THE STANDARDS FOR BIPOLAR EXCELLENCE (STABLE) PROJECT- A BIPOLAR DISORDER QUALITY IMPROVEMENT INITIATIVE TO DEVELOP ANDVALIDATE EVIDENCE-BASED PERFORMANCE MEASURES FOR ENDORSEMENT BY THE NATIONAL QUALITY FORUM (NQF)

    May 1, 2008, 00:00

  • PCN14 A SYSTEMATIC REVIEW OF ECONOMIC ANALYSES OF HER2 TESTING TRASTUZUMAB THERAPY

    May 1, 2008, 00:00

  • DU5 IMPACT OF FORMULARY RESTRICTIONS ON ADHERENCE TO SECOND GENERATION ANTIPSYCHOTICS

    May 1, 2008, 00:00

  • PCV5 THE IMPACT OF PHARMACISTS INTERVENTIONS- SENSITIVITY ON PATIENT OUTCOMES IN HYPERLIPIDEMIA MANAGEMENT

    May 1, 2008, 00:00

  • PND48 THE USE OF BOTULINUM TOXIN TYPE A FOR MIGRAINE OR HEADACHE IN THE USA

    May 1, 2008, 00:00

  • PRS25 VALIDATION OF CLAIMS-BASED PERSISTENT ASTHMA SEVERITY CLASSIFICATION

    May 1, 2008, 00:00

  • MD6 INFLUENCE OF MEDICARE CLAIM-PAYING AGENTSS LYMPHOMA PATIENTS

    May 1, 2008, 00:00

  • PCV102 THE ASSESSING CARDIOVASCULAR TARGETS (ACT 07) PROGRAM- PRELIMINARY RESULTS FROM A PRACTICE REFLECTIVE ASSESSMENT ACROSS CANADA

    May 1, 2008, 00:00

  • PHP41 PATIENT RACE AND MEDICATION CHOICE FOR HYPERCHOLESTEROLEMIA, HYPERTENSION, AND DIABETES

    May 1, 2008, 00:00

  • PUK15 COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)

    May 1, 2008, 00:00

  • Assessing the Impact of Censoring of Costs and Effects on Health-Care Decision-Making- an Example Using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study

    May 1, 2008, 00:00

  • PSS3 COMPARING THE EFFECTIVENESS OF CORTISPORIN VS. CIPRODEX FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2008, 00:00

  • PCV98 THE EFFECTS OF STEP THERAPY- LOOKING BEYOND IMPACTS ON PRESCRIBING RATES AND COSTS

    May 1, 2008, 00:00

  • PCN12 USE OF HEALTH RESOURCES IN LUNG CANCER PATIENTS- A BRAZILIAN ANALYSIS IN THE PRIVATE PAYER PERSPECTIVE

    May 1, 2008, 00:00

  • PSY46 PSYCHOMETRIC ANALYSIS OFTHE THREE-FACTOR EATING QUESTIONNAIRE- RESULTS FROM A LARGE DIVERSE SAMPLE OF OBESE AND NON-OBESE SUBJECTS

    May 1, 2008, 00:00

  • PND30 PERFORMANCE OFTHE EURO QOL 5D (EQ-5D) IN PRIMARY CARE PATIENTS WITH CO-MORBID INSOMNIA

    May 1, 2008, 00:00

  • PHP59 DRUG THERAPY PROBLEMS- DOES PHARMACISTS INTERVENTION SAVE COST?

    May 1, 2008, 00:00

  • PHP65 THE ROLE OF THE ACADEMY OF MANAGED CARE PHARMACY (AMCP) FORMAT IN MANAGED CARE FORMULARY AND COVERAGE DECISIONMAKING

    May 1, 2008, 00:00

  • PHP15 EVALUATING THE USE OF PROVISIONAL PATENTS BYTHE PHARMACEUTICAL INDUSTRY-THE EXPERIENCE OF THE UNITED STATES

    May 1, 2008, 00:00

  • PMH48 BETTER PERSISTENCE ONTREATMENT WITH ESCITALOPRAM COMPARED WITH CITALOPRAM

    May 1, 2008, 00:00

  • PGI27 INFLAMMATORY BOWEL DISEASES (IBD) PATIENTS PROFILE- FACTS EXTRACTED FROM A MULTICENTER RETROSPECTIVE STUDY

    May 1, 2008, 00:00

  • PSY14 ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR MULTIPLE MYELOMA IN SCOTLAND IN PATIENTSWHO HAVE RECEIVED ONE PRIOR THERAPY

    May 1, 2008, 00:00

  • PMH42 IMPACT OF RISPERIDONE LONG-ACTING INJECTION VERSUS ORAL ANTIPSYCHOTIC TREATMENTS ON HOSPITALIZATION IN SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PMC37 ACCESS TO PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS ANDTHEIR TRANSLATIONS IN THE LIGHT OF FDA RECOMMENDATIONS

    May 1, 2008, 00:00

  • PHP24 THE IMPACT OF BENEFIT PLAN DESIGN ON COST AND HEALTH OUTCOMES

    May 1, 2008, 00:00

  • PHP81 PROGRESSIVE LICENSING AND VALUE FOR MONEY- USE OF RESPONDERANALYSIS IN ECONOMIC EVALUATION

    May 1, 2008, 00:00

  • PND35 IMPACT OF NATALIZUMAB ON PATIENT OUTCOMES IN MULTIPLE SCLEROSIS- A CROSS-SECTIONAL SURVEY

    May 1, 2008, 00:00

  • DB1 REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE

    May 1, 2008, 00:00

  • PHP37 THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS BY SERUM DIGOXIN LEVELS DURING HOSPITALIZATION

    May 1, 2008, 00:00

  • PGI14 COST-EFFECTIVENESS OF PROTON PUMP INHIBITORS FOR PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE- SHOULD EMERGING SAFETY CONCERNS AFFECT THERAPEUTIC DECISION-MAKING?

    May 1, 2008, 00:00

  • PHP64 THE EFFECT OF THE PERFORMANCE VOLUME LIMIT (PVL) ON THE DRG FINANCING OF THE HUNGARIAN HOSPITALS

    May 1, 2008, 00:00

  • PRS17 ECONOMIC OUTCOMES IN PATIENTS WITH CYSTIC FIBROSIS- A REVIEW OF THE LITERATURE

    May 1, 2008, 00:00

  • DH4 MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES- ANALYSIS OF NEW DRUGS APPROVED FROM 1980 TO 2007

    May 1, 2008, 00:00

  • PSY38 FACTORS ASSOCIATED WITH LOWER HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN ADULTS WITH FACTORVIII DEFICIENCY-THE HEMOPHILIA UTILIZATION GROUP STUDY-PART V (HUGS-V)

    May 1, 2008, 00:00

  • PCV41 COMPARISON OF COST-EFFECTIVENESS OF POM (PRESCRIPTION ONLY) STATINS; OTC (OVERTHE COUNTER) STATIN AND PLANT STEROL / STANOL PRODUCTS FOR PRIMARY CVD (CARDIOVASCULAR DISEASE) PREVENTION IN THE UNITED KINGDOM FROM THE PATIENTS PERSPECTI ...

    May 1, 2008, 00:00

  • PMS22 ECONOMIC IMPACT OF ALLOPURINOL HYPERSENSITIVITY SYNDROME

    May 1, 2008, 00:00

  • PMH75 IMPACT OF ALTERNATIVE TREATMENTS ON POST-TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PCN10 CANCER RISK BETWEEN ATORVASTATIN AND SIMVASTATIN IN THE LOUISIANA MEDICAID PATIENTS

    May 1, 2008, 00:00

  • PSS49 HEALTH CARE UTILIZATION INCREASES IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS

    May 1, 2008, 00:00

  • PIN1 TREATMENT OF HEPATITIS C INFECTION FOR CURRENT OR FORMER SUBSTANCE ABUSERS IN A COMMUNITY SETTING

    May 1, 2008, 00:00

  • PHP49 FRAMEWORK AND METHODOLOGYTO IDENTIFY AND ASSESS PHARMACIST-SENSITIVE OUTCOMES IN COLLABORATIVE MEDICATION MANAGEMENT

    May 1, 2008, 00:00

  • PCV38 BOSENTAN IS A COST-EFFECTIVE TREATMENT FOR UNITED KINGDOM PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION OF WHO CLASS III

    May 1, 2008, 00:00

  • PMH43 MENTAL HEALTH CARE RESOURCE USE BEFORE AND AFTER INITIATION OF PALIPERIDONE ER IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PIH10 THE COST-EFFECTIVENESS OF ROUTINE SCREENING FOR VASA PREVIA AT 18-20 WEEKS GESTATION IN ONTARIO

    May 1, 2008, 00:00

  • PSY36 COMPLEMENTARY AND ALTERNATIVE MEDICINE AND HEALTH CARE UTILIZATION IN PATIENTS WITH NON-CANCER CHRONIC PAIN

    May 1, 2008, 00:00

  • PRS5 IMPACT OF TOBACCO SMOKE EXPOSURE ON EXACERBATION FREQUENCY, SEVERITY, AND INHALER USE IN ASTHMATIC CHILDREN

    May 1, 2008, 00:00

  • PCV72 ENHANCING THE EFFECTIVENESS OF COMMUNITY STROKE RISK SCREENINGS RANDOMIZED CONTROL TRIAL

    May 1, 2008, 00:00

  • PRS12 INCREMENTAL COST-EFFECTIVENESS OF COMBINATION INHALERTHERAPY IN MODERATE TO SEVERE COPD

    May 1, 2008, 00:00

  • PHP28 THE PROCESS OF UPDATINGTHE NATIONAL LIST OF HEALTH SERVICES IN ISRAEL- IS IT LEGITIMATE? IS IT FAIR?

    May 1, 2008, 00:00

  • PMC52 THE DEVELOPMENT OFTHE PROGNOSTIC PROPENSITY SCORE- UTILIZED TO PROVIDE PHYSICIANS WITH DETAILED EVIDENCE TO ALLOW FOR OPTIMAL PRESCRIBING

    May 1, 2008, 00:00

  • PHP20 PREDICTORS OF ENROLLMENT IN MEDICARE PART D-THE EXPERIENCE OF MEDICARE DRUG DEMONSTRATION PARTICIPANTS WITH RHEUMATOID ARTHRITIS AND MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PMH85 PSYCHOTHERAPY AND MEDICATION USE AMONG DEPRESSION PATIENTS

    May 1, 2008, 00:00

  • PCN43 THE ASSOCIATION OF TUMOR HISTOLOGY WITH FIRST-LINE TREATMENT AND LIFETIME MEDICAL-CARE COSTS AMONG ELDERLY STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH COMMONLY USED DOUBLET THERAPIES AMONG

    May 1, 2008, 00:00

  • AC8 ASSOCIATION OF MEASURES OF MEDICATION ADHERENCE AND SEVERE RELAPSES WITH MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPY

    May 1, 2008, 00:00

  • PHP13 CONTROLLED SUBSTANCEWASTE IN HOME HOSPICE SETTINGS

    May 1, 2008, 00:00

  • PIN48 TRENDS FOR NOSOCOMIAL SOFT TISSUE INFECTIONS, STAPHLOCOCCOUS AUREUS INFECTIONS, AND MRSA IN US HOSPITALS- 1998-2004

    May 1, 2008, 00:00

  • PMH64 MAJOR DEPRESSIVE DISORDER- A COMPREHENSIVE LITERATURE REVIEW OFTHE BURDEN OF ILLNESS IN NORTH AMERICA

    May 1, 2008, 00:00

  • PDB33 COST MINIMIZATION ANALYSIS OF DIFFERENT GROWTH HORMONE DEVICES BASED ON TIME-AND-MOTION SIMULATIONS

    May 1, 2008, 00:00

  • PSY42 EFFECTIVENESS OF ONCE-DAILY EXTENDED-RELEASE (ER) TRAMADOL IN ACHIEVING CLINICALLY MEANINGFUL IMPROVEMENT IN FUNCTIONING

    May 1, 2008, 00:00

  • PSS13 COST-EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN) AS COMPARED WITH RANIBIZUMAB (LUCENTIS) FOR TREATING IN AGE-RELATED MACULAR DEGENERATION (AMD)

    May 1, 2008, 00:00

  • PDB16 THE BUDGET IMPACT OFAPIDRA(r) (INSULIN GLULISINE) REIMBURSEMENT IN POLAND

    May 1, 2008, 00:00

  • PHP52 CHANGES IN PHARMACIST-PROVIDED MEDICATION THERAPY MANAGEMENT SERVICES- ANALYSIS OF ONE INNOVATIVE COMPANYS MTM SERVICE CLAIMS OVERTIME

    May 1, 2008, 00:00

  • PHP2 ADHERENCE TO EVIDENCE-BASED GUIDELINES AND MEDICATION COMPLIANCE FOR MULTIPLE CHRONIC DISEASES IN A MANAGED CARE DATABASE

    May 1, 2008, 00:00

  • PRS19 SMOKING-CESSATION THERAPY USING VARENICLINE- THE COST-UTILITY OF AN ADDITIONAL 12-WEEK COURSE OF VARENICLINE FOR THE MAINTENANCE OF SMOKING ABSTINENCE

    May 1, 2008, 00:00

  • PND26 COMPARISON OF COMPLIANCE AND PERSISTENCE WITH IMMUNOMODULATING AGENTS FOR MULTIPLE SCLEROSIS IN A COMMERCIALLY INSURED POPULATION

    May 1, 2008, 00:00

  • PRS10 ECONOMIC AND CLINICAL OUTCOMES OF OMALIZUMAB USE FORTREATING ASTHMA IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • MD1 MEDICARE PART D- EARLY EVIDENCE ON PRESCRIPTION DRUGTREATMENT PATTERNS, HOSPITALIZATION OFFSETS AND MEDICARE SPENDING

    May 1, 2008, 00:00

  • PHP3 IS THERE AN ACCEPTABLE LEVEL OF MEDICATION ADHERENCE? A REVIEW OF RETROSPECTIVE ADHERENCE EVALUATION STUDIES

    May 1, 2008, 00:00

  • PMS4 THE EFFECT OF HOSPITAL VOLUME ON 30 DAYS MORTALITY FOLLOWING HIP FRACTURE

    May 1, 2008, 00:00

  • PCN34 COST-EFFECTIVENESS OF GEFITINIB FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER- A MARKOV MODEL-BASED ANALYSIS

    May 1, 2008, 00:00

  • PIN11 COST SAVINGS FROM REDUCED HIV INCIDENCE ESTIMATES

    May 1, 2008, 00:00

  • PMH22 ECONOMIC ASSESSMENT OF THREE COMMONLY USED ANTIPSYCHOTIC AGENTS IN THE PUBLIC SECTOR OF HONG KONG USING A DECISION ANALYTIC MODEL

    May 1, 2008, 00:00

  • PGI10 DOES THE DOSING FREQUENCY OF PROTON PUMP INHIBITORS (PPIS) AFFECT SUBSEQUENT RESOURCE UTILIZATION AND COSTS AMONG PATIENTS DIAGNOSED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)?

    May 1, 2008, 00:00

  • PIN16 COST-EFFECTIVENESS OF POSACONAZOLE VS. FLUCONAZOLE IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH GRAFT-VERSUS-HOST DISEASE IN CANADA

    May 1, 2008, 00:00

  • PCN73 COMPARISON OF SURVIVAL QUALITY FROM TWO TREATMENT STRATEGIES FORACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CHILDHOOD- DANA-FARBER CANCER INSTITUTE (DFCI) AND BERLIN-FRANKFURT-MONSTER (BFM)

    May 1, 2008, 00:00

  • PMC18 COMPARISONS OF DATA MINING ALGORITHMS FOR ADVERSE DRUG REACTIONS- AN EMPIRICAL STUDY BASED ONTHE ADVERSE EVENT REPORTING SYSTEM OFTHE FOOD AND DRUG ADMINISTRATION

    May 1, 2008, 00:00

  • PIN52 PRESCRIBING TRENDS IN ANTIVIRAL PRESCRIPTIONS AMONG PATIENTS WITH INFLUENZA IN THE UNTED STATES FROM 1999-2005

    May 1, 2008, 00:00

  • PMH68 CHANGES OVER TIME IN PATIENT CHARACTERISTICS FOLLOWINGTHE INTRODUCTION OF DULOXETINE- A 24 MONTHS STUDY

    May 1, 2008, 00:00

  • AC7 COMPARING ADHERENCE TO FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PND14 ECONOMIC EVALUATION OF SATIVEX FOR TREATMENT OF NEUROPATHIC PAIN IN PATIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PDB66 HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC

    May 1, 2008, 00:00

  • PCV7 RISK OF HOSPITALIZATION ASSOCIATED WITH BETA-BLOCKERTHERAPY IN PATIENTS OF CHRONIC HEART FAILURE AND DIABETES- A MEDIC AID STUDY

    May 1, 2008, 00:00

  • PUK8 A REVIEW- DIFFERING COSTS AND EFFECTS IN ECONOMIC EVALUATIONS OF TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER

    May 1, 2008, 00:00

  • PRS22 EFFECT OF PATIENTS OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH OMALIZUMAB (XOLAIR) THERAPY FOR ALLERGIC ASTHMA

    May 1, 2008, 00:00

  • PCV53 DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE- COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA

    May 1, 2008, 00:00

  • PHP17 HOW MANDATORY PRICE REDUCTION OF REIMBURSED PHARMACEUTICALS COULD RESULT IN INCREASED PHARMACEUTICAL EXPENDITURE?

    May 1, 2008, 00:00

  • PND7 BUDGET IMPACT OFTRANSDERMAL ADHESIVES OF RIVASTIGMINE IN BRAZILIAN PUBLIC HEALTH SYSTEM

    May 1, 2008, 00:00

  • PHP42 PHYSICIANS VIEWS REGARDING PRESCRIPTION DRUG ACCESS UNDER MEDICARE PART D

    May 1, 2008, 00:00

  • PHC10 AN ASSESSMENT OF HOSPITAL COSTS AND REIMBURSEMENT AMONG TOTAL HIP OR KNEE ARTHROPLASTY PATIENTS IN THE UNITED STATES THAT EXPERIENCE VENOUS THROMBOEMBOLISM

    May 1, 2008, 00:00

  • DH3 THE IMPACT OF DRUG VINTAGE ON PATIENT SURVIVAL- A PATIENT-LEVEL APPROACH USING QUEBECS PROVINCIAL HEALTH PLAN DATA

    May 1, 2008, 00:00

  • PCV15 SEASONAL VARIATION OF HEART ATTACKS IN WOMEN

    May 1, 2008, 00:00

  • PRS16 INCREMENTAL DIRECT MEDICAL EXPENDITURES ASSOCIATED WITH ADULT ASTHMA IN THE UNITED STATES

    May 1, 2008, 00:00

  • PSS45 VALUE OF DRIVING FOR PATIENTS WITH GLAUCOMA- WILLINGNESS TO PAY

    May 1, 2008, 00:00

  • PR4 EVALUATION OF IMPACT OF ORALTOPOTECAN ON HEALTH-RELATED QUALITY OF LIFE IN RELAPSED SMALL CELL LUNG CANCER

    May 1, 2008, 00:00

  • PUK13 A COST MINIMIZATION ANALYSIS OF EPOETIN ZETA FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE

    May 1, 2008, 00:00

  • PRS6 A COST-EFFECTIVENESS MODEL FOR SMOKING CESSATION THERAPY USING VARENICLINE

    May 1, 2008, 00:00

  • PDB45 CANADIAN COST UTILITY ANALYSIS COMPARING EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE TWO DIABETES

    May 1, 2008, 00:00

  • PCV103 THE PATIENT SAFETY STANDARDS OF ACUTE STROKE MANAGEMENT IN HUNGARY

    May 1, 2008, 00:00

  • PMC14 EXPLORING CANDIDATE DIFFERENCES BETWEEN DRUG COHORTS PRIOR TO EXPOSURE- A SYSTEMATIC APPROACH USING MULTIPLE OBSERVATIONAL DATABASES

    May 1, 2008, 00:00

  • PND44 CANADIAN PATIENT SURVEY TO ASSESS PATIENTS PLIGHT TO DYSTONIA DIAGNOSES AND BOTULINUM TOXIN TYPE A TREATMENT

    May 1, 2008, 00:00

  • PND12 COST-EFFECTIVENESS ASSESSMENT OF ANTIEPILEPTIC DRUGS AS ADJUVANTTREATMENTS FOR THE MANAGEMENT OF REFRACTORY PARTIAL SEIZURES IN ADULT MEXICAN PATIENTS

    May 1, 2008, 00:00

  • PND31 CO-MORBID INSOMNIA IN PRIMARY CARE PATIENTS AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQL) INDEPENDENT OF OTHER FACTORS

    May 1, 2008, 00:00

  • PRS29 PATIENT, CAREGIVER, AND PHYSICIAN PERCEPTIONS OF MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE- FINDINGS FROM QUALITATIVE RESEARCH

    May 1, 2008, 00:00

  • PGI9 DEVELOPMENT OF A CLAIMS-BASED MARKOV MODEL FOR CROHNS DISEASE

    May 1, 2008, 00:00

  • PSS35 THE IMPACT OF GLAUCOMA ON QUALITY OF LIFE- COMPARISON WITH THE CHRONIC DISEASES OSTEOPOROSIS. TYPE 2 DIABETES MELLITUS, AND DEMENTIA

    May 1, 2008, 00:00

  • PRS33 TREATMENT SATISFACTION QUESTIONNAIRES IN ASTHMA AND OTHER CHRONIC DISEASES

    May 1, 2008, 00:00

  • CV2 THE COST-EFFECTIVENESS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE (HF)-AN ASSESSMENT OF THE LOW LEFT VENTRICULAR EJECTION FRACTION (LOW-LVEF) TRIALS IN THE CANDESARTAN-IN-HEART-FAILURE-ASSESSMENT-OF-REDUCTION-IN-MORTALITYA ...

    May 1, 2008, 00:00

  • PSS14 COST-EFFECTIVENESS OF THE TREATMENT FOR MODERATE TO SEVERE PSORIASIS IN MEXICO- INFLIXIMAB, ETANERCEPT AND EFALIZUMAB

    May 1, 2008, 00:00

  • PND37 REDUCTIONS IN FREQUENCY AND INTENSITY OF PAIN WITH BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF CERVICAL DYSTONIA

    May 1, 2008, 00:00

  • PUK23 EVALUATION OF FACE AND CONTENT VALIDITY OF NOCTURIA QUALITY OF LIFE QUESTIONNAIRE (N-QOL)

    May 1, 2008, 00:00

  • PCV47 MEDICARE OUTLIER PAYMENTS FOR CORONARY ARTERY BYPASS GRAFTING

    May 1, 2008, 00:00

  • PCN5 META-ANALYSIS ON THE MORBIDITY AND MORTALITY OF CLODRONATE, PAMIDRONATE AND ZOLEDRONATE IN PATIENTS WITH BONE METASTASES

    May 1, 2008, 00:00

  • PMH35 COST-EFFECTIVENESS OF ORALLY DISSOLVING OLANZAPINE TABLETS IN THE TREATMENT OF SCHIZOPHRENIA IN THE USA

    May 1, 2008, 00:00

  • PDB72 THE NEED FOR EARLIER INSULIN INITIATION AND INTENSIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES- EVIDENCE FROM HEALTH CLAIMS AND LABORATORY DATABASE

    May 1, 2008, 00:00

  • PIN18 THE IMPACT OF PEDIATRIC ADVERSE EVENTS ON THE COST-EFFECTIVENESS OF OSELTAMIVIR

    May 1, 2008, 00:00

  • PGI23 PATIENT REPORTED PREVALENCE AND SEVERITY OF CONSTIPATION IN HOSPICE PATIENTS

    May 1, 2008, 00:00

  • PMH51 A NEW MEASURE OF ADHERENCE-THE DAILY POSSESSION RATIO (DPR)- COMPARISONS WITHTHE MEDICATION POSSESSION RATIO (MPR) IN THE PRESENCE OF MEDICATION SWITCHING ANDTHERAPEUTIC DUPLICATION

    May 1, 2008, 00:00

  • PCV1 A MODIFIED RXRISK-V COMORBIDITY INDEX PREDICTS ADHERENCE WITH LIPID LOWERINGTHERAPY (LLT)

    May 1, 2008, 00:00

  • PGI24 RACIAL, SOCIAL, AND ECONOMIC DISPARITIES IN KNOWLEDGE AND CARE SEEKING BEHAVIORS FOR GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)

    May 1, 2008, 00:00

  • PUK9 HEALTH ECONOMIC EVALUATION OF PARICALCITOL COMPARED TO NON-SELECTIVE VITAMIN D RECEPTOR ACTIVATOR FORTHETREATMENT OF SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE PATIENTS- US PERSPECTIVE

    May 1, 2008, 00:00

  • PDB43 DETERMINANTS OF THE ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE

    May 1, 2008, 00:00

  • PHP10 CREATION OF A RISK RATING SYSTEMTO COMMUNICATE DRUG SAFETY INFORMATIONTO CONSUMERS

    May 1, 2008, 00:00

  • PRS39 THE IMPACT OF FORMULARY POLICIES ON THE USE OF MEDICATION FOR RESPIRATORY DISEASE- A COMPARISON OF DRUG UTILIZATION IN THE PROVINCES OF ONTARIO AND ALBERTA

    May 1, 2008, 00:00

  • PSY43 DISCOVERING THE STRUCTURE OFTHE POWER OF FOOD SCALE (PFS) IN OBESE PATIENTS

    May 1, 2008, 00:00

  • PCN78 DERIVATION OF UTILITY VALUES FROM EORTC QLQC30 IN LUNG CANCER

    May 1, 2008, 00:00

  • PSY40 SYSTEMATIC REVIEW OFTHE PSYCHOMETRIC PROPERTIES OFTHE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-ANEMIA (FACT-AN) FOR ANEMIC CANCER PATIENTS

    May 1, 2008, 00:00

  • PND17 SEVERITY OF ILLNESS AMONG PERSONS WITH AND WITHOUT MULTIPLE SCLEROSIS- AN ANALYSIS OF COST QUINTILES

    May 1, 2008, 00:00

  • PMC35 A SYSTEMATIC REVIEW OF APPLICATIONS OF CONJOINT ANALYSIS IN MEDICINE

    May 1, 2008, 00:00

  • PGI19 DEVELOPMENT OF AN HIV-RELATED, DIARRHEA IMPACT, PATIENT REPORTED OUTCOME (PRO) QUESTIONNAIRE

    May 1, 2008, 00:00

  • PDB34 ASSESSING DIFFERENCES IN UTILIZATION AND COSTS BETWEEN INSULIN DETEMIR (LEVEMIR) AND INSULIN GLARGINE (LANTUS) USERS

    May 1, 2008, 00:00

  • PSY9 RISK FACTORS AND RISKS ASSOCIATED WITH HOSPITAL STAYS IN PATIENTS WITH MYALGIA

    May 1, 2008, 00:00

  • PCV40 COST-EFFECTIVENESS ANALYSIS OF DRUG-ELUTING STENT VS BARE METAL STENT IN PATIENTS WITH ISCHAEMIC HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE.

    May 1, 2008, 00:00

  • PMC43 USE OF BACKTRANSLATION REVIEW IN THE TRANSLATION OF PRO INSTRUMENTS-SOME EXAMPLES

    May 1, 2008, 00:00

  • PMH76 COST ESTIMATION OF PSYCHIATRIC CARE IN THE JAPANESE HOSPITAL USING SYSTEM DYNAMICS SIMULATION

    May 1, 2008, 00:00

  • PIN8 BUDGET IMPACT OF ADDING DORIPENEMTO A HOSPITAL FORMULARY

    May 1, 2008, 00:00

  • PCV43 OPTIMIZATION OF DIAGNOSIS AND TREATMENT OF CORONARY ARTERY DISEASE IN CHINA WITH USE OF CORONARY CT ANGIOGRAPHY

    May 1, 2008, 00:00

  • CV1 EFFECTIVENESS OF COMBINED BETA-BLOCKER AND ACEI OR ARBTHERAPY IN CHRONIC HEART FAILURE

    May 1, 2008, 00:00

  • PDB20 COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE I DIABETES MELLITUS (TIDM) IN THE CANADIAN PAYER SETTING- MODELING ANALYSIS USING A RANDOMIZED CONTROLLED TRIAL

    May 1, 2008, 00:00

  • Uncertainty in Decision-Making- Value of Additional Information in the Cost-Effectiveness of Lifestyle Intervention in Overweight and Obese People

    May 1, 2008, 00:00

  • PMH87 SUPPORTING PRODUCT CLAIMS IN DRUG DEVELOPMENT- A FRAMEWORK FOR INTEGRATING PATIENT REPORTED OUTCOMES AND HEALTH ECONOMICS CONCEPTS AND ENDPOINTS

    May 1, 2008, 00:00

  • PGI25 COSTS OF A PRIOR AUTHORIZATION ON LUBIPROSTONE FOR ELDERLY (AGE 65) PATIENTS WITH CHRONIC CONSTIPATION IN A MEDICARE PART D POPULATION

    May 1, 2008, 00:00

  • PCN49 THE COST OF TREATING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARYTO BREAST, LUNG, OR PROSTATE CANCER

    May 1, 2008, 00:00

  • PGI4 A BRAZILIAN CROSS SECTIONAL STUDY TO EVALUATE HOSPITALIZATION AMONG MODERATE AND SEVERE CROHNS DISEASE PATIENTS

    May 1, 2008, 00:00

  • PIN40 ASSESSMENT OF THE CROSS-CULTURAL VALIDITY OF AN HIV SYMPTOM DISTRESS MODULE IN AN INTERNATIONAL HIV CLINICAL TRIAL

    May 1, 2008, 00:00

  • PHP33 HERB/DIETARY SUPPLEMENT AND PRESCRIPTION DRUG USE TRENDS AMONG US ADULTS, 1999-2004

    May 1, 2008, 00:00

  • PDB4 ESTIMATION OF STUDY POPULATION SIZE FOR EFFECTIVENESS OUTCOMES AT 6 AND 12 MONTHS VIA ELECTRONIC MEDICAL RECORDS

    May 1, 2008, 00:00

  • PCN28 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB-CHOP VS. CHOP ON NON-HODGKIN LYMPHOMA PATIENTS IN THE MEXICAN CONTEXT

    May 1, 2008, 00:00

  • PHP39 THE EPIDEMIOLOGY AND OUTCOMES OF PATIENTS TREATED WITH HEPARIN DURING HOSPITALIZATION

    May 1, 2008, 00:00

  • PCV84 HEALTH CARE UTILIZATION ASSOCIATED WITH DEPRESSION FOLLOWING THROMBOTIC CARDIOVASCULAR EVENTS IN ELDERLY MEDICARE BENEFICIARIES

    May 1, 2008, 00:00

  • PRS42 ASTHMA DISEASE BURDEN, EVIDENTIARY REQUIREMENTS, AND FORMULARY CONSIDERATIONS AMONG MANAGED CARE AND EMPLOYER DECISION MAKERS REGARDING INHALED CORTICOSTEROIDS (ICS)

    May 1, 2008, 00:00

  • PCASE2 THE ROLE OF ECONOMIC EVALUATION IN CHANGING DECISION-MAKER BEHAVIOURS -A CASE STUDY FROM TRINIDAD AND TOBAGO

    May 1, 2008, 00:00

  • PIN2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF PEGYLATED INTERFERON, LAMIVUDINE, ADEFOVIR AND ENTECAVIR FORTHETREATMENT OF HEPATITIS B

    May 1, 2008, 00:00

  • PHP67 THRESHOLD VALUE FOR A QALY-CORRELATION WITH DISEASE SEVERITY AND DECISION UNCERTAINTY

    May 1, 2008, 00:00

  • PRS2 A MIXED TREATMENT COMPARISON META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF PHARMACOLOGIC TREATMENTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2008, 00:00

  • PIN37 AN EXAMINATION OF THE CORRELATION BETWEEN QUALITY OF PATIENT CARE AND PATIENT RACE OR SOCIAL CLASS IN INPATIENT APPENDICITIS CASES

    May 1, 2008, 00:00

  • PSY5 CROSS-CULTURAL COMPARISONS OFTHE OVERWEIGHT/OBESE POPULATION IN THE US AND EUROPE

    May 1, 2008, 00:00

  • PMH24 INITIATING TREATMENT ON GENERIC ANTIDEPRESSANTS MAY NOT SAVE HEALTH CARE COSTS

    May 1, 2008, 00:00

  • CN4 COSTS ASSOCIATED WITH NEUTROPENIA IN ELDERLY PATIENTS TREATED FIRST-LINE FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

    May 1, 2008, 00:00

  • PMC51 MEDICATION ADHERENCE- A CONCEPTUAL REVIEW

    May 1, 2008, 00:00

  • PMS36 IMPROVEMENT IN SLEEP QUALITY FROM ABATACEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2008, 00:00

  • PDB68 AN ASSESSMENT OF THE IMPACT OF THE COVERAGE GAP UPON MEDICARE PART D BENEFICIARIES UTILIZING INSULIN

    May 1, 2008, 00:00

  • PIN29 COST-EFFECTIVENESS EVALUATION OF THREE HEALTH CARE DELIVERY MODELS FOR HIV POSITIVE PATIENTS IN COLOMBIA

    May 1, 2008, 00:00

  • PCN8 IMPROVED SURVIVAL OF PATIENTS WITH GLIOBLASTOMA MULTIFORME BYTEMOZOLOMIDE AS ADJUVANT THERAPY- A RETROSPECTIVE COHORT STUDY

    May 1, 2008, 00:00

  • PSY20 COST-EFFECTIVENESS ANALYSIS OF IMMUNOSUPPRESSIVE TREATMENTS FOR BONE MARROWTRANSPLANTATION IN PATIENTS WITH APLASTIC ANEMIA IN MEXICO

    May 1, 2008, 00:00

  • PR3 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

    May 1, 2008, 00:00

  • PMS14 A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL AGENTS FOR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS FOLLOWING INADEQAUTE RESPONSE TO METHOTREXATE

    May 1, 2008, 00:00

  • PMH77 ANTIPSYCHOTIC METABOLIC PROPENSITY AND POLYTHERAPY- INFLUENCE ON HOSPITALIZATION

    May 1, 2008, 00:00

  • PHP14 ESTIMATION OF USAGE OF NEW DRUG AFTER REIMBURSEMENT FOR BUDGET IMPACT ANALYSIS

    May 1, 2008, 00:00

  • PCV85 IMPACT OF MEDICARE PART D IMPLEMENTATION ON STATIN UTILIZATION AND MARKET SHARE IN STATE MEDICAID PROGRAMS

    May 1, 2008, 00:00

  • HP1 A COMPARISON OFTHREETECHNOLOGY APPRAISAL SYSTEMS; NICE, SMC AND CADTH

    May 1, 2008, 00:00

  • PSS9 A COST-EFFECTIVENESS ANALYSIS OFTNF-ALPHA INHIBITORS IN COMPARISON TO OTHER STRATEGIES IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS- A DECISION ANALYSIS MODEL

    May 1, 2008, 00:00

  • PCN59 TIME COSTS AND OUT-OF-POCKET COSTS OF PROSTATE CANCER SURVIVORS IN ONTARIO, CANADA

    May 1, 2008, 00:00

  • PMC28 RASCH PARTIAL CREDIT ANALYSIS OFTHE SF-12V2 USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2008, 00:00

  • PMH80 THE CHANGE OF PRICES AND EXPENDITURES OFTHE ORIGINAL AND GENERIC DRUGS OF FLUOXETINE-A LONGITUDINAL ANALYSIS ON REIMBURSEMENT DATABASE OFTHE NATIONAL HEALTH INSURANCE

    May 1, 2008, 00:00

  • PHP36 RELATIONSHIP OF DOCTOR SHOPPING AND POLYPHARMACY-A NATIONWIDE STUDY IN TAIWAN

    May 1, 2008, 00:00

  • CA2 THE USE OF RESEARCH ABSTRACTS IN FORMULARY DECISION MAKING BYTHE ONTARIO CANCER DRUG APPROVAL COMMITTEE

    May 1, 2008, 00:00

  • PSS46 PROSTAGLANDIN ANALOG USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMAA NETHERLANDS POPULATION BASED ANALYSIS

    May 1, 2008, 00:00

  • PSS39 ESTIMATING HEALTH RELATED UTILITY FROM SYMPTOM SEVERITY IN ATOPIC DERMATITIS (ECZEMA)

    May 1, 2008, 00:00

  • PSY12 PROJECTED COST OF CARDIOMETABOLIC RISK FACTORS IN COMMERCIALLY INSURED NORMAL AND OVERWEIGHT PRIMARY CARE PATIENTS

    May 1, 2008, 00:00

  • PRS32 IMPACT OF UNCONTROLLED ASTHMA ON PRODUCTIVITY AND ACTIVITY IMPAIRMENT

    May 1, 2008, 00:00

  • PUK4 COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN MEXICO

    May 1, 2008, 00:00

  • PGI6 COST-EFFECTIVENESS RECOMBINANT FACTORVIIA USE IN ORTHOTOPIC LIVER TRANSPLANT

    May 1, 2008, 00:00

  • PDB39 FACTORS ASSOCIATED WITH HIGH TREATMENT CHARGES IN PATIENTS WITH DIABETIC NEUROPATHY

    May 1, 2008, 00:00

  • OM3 WAS IT NICE FORYOU? ESTIMATING SUBGROUP QUALITY OF LIFE TARIFFS FROM CONJOINT ANALYSES- RESULTS FROM A BEST-WORST SCALING STUDY

    May 1, 2008, 00:00

  • PMS23 MODELLING OF BURDEN OF FEMORAL NECK FRACTURE IN 2007 FROM PURCHASERS POINT OF VIEW

    May 1, 2008, 00:00

  • PND36 OBSERVED DIFFERENCES BETWEEN DAILY DIARY AND WEEKLY REPORT OF CYSTIC FIBROSIS SYMPTOMS

    May 1, 2008, 00:00

  • PMC24 INVERSE PROBABILITY WEIGHTED RANDOM EFFECT MODELS FOR ESTIMATION OF CENSORED OUTCOMES VARIABLES

    May 1, 2008, 00:00

  • PIN41 COMPLEMENTARY AND ALTERNATIVE MEDICATION USE AND ADVERSE EVENTS IN HIV-INFECTED PATIENTS

    May 1, 2008, 00:00

  • PSS19 A PHARMACOECONOMIC EVALUATION OF PEGAPTANIB FOR THE MANAGEMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) IN MEXICO

    May 1, 2008, 00:00

  • PIN10 COMPARATIVE (POSACONAZOLE VS. OTHER SYSTEMIC ANTIFUNGALS) ALL-CAUSE MORTALITY AND COST ANALYSIS IN PATIENTS WITH REFRACTORY INVASIVE ASPERGILLOSIS

    May 1, 2008, 00:00

  • PIH13 A CONCEPTUAL FRAMEWORK TOWARD A MODIFIED REFERENCE CASE FOR DEVELOPING COUNTRIES- INCORPORATING DONOR FUNDING FLOWS IN COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PCV12 METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN

    May 1, 2008, 00:00

  • PSY10 A NOVEL APPROACHTO ADJUST FOR THE IMPACT ON SURVIVAL RESULTING FROM PATIENT CROSS-OVER FROM CONTROLTO EXPERIMENTAL TREATMENT IN CLINICAL TRIALS

    May 1, 2008, 00:00

  • PMH38 GENERALIZED ANXIETY DISORDER- A COMPREHENSIVE LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN NORTH AMERICA

    May 1, 2008, 00:00

  • PND28 IMPROVEMENTS IN QUALITY OF LIFE FOLLOWING TREATMENT WITH BOTULINUM TOXIN TYPE A FOR CERVICAL DYSTONIA

    May 1, 2008, 00:00

  • PDB70 IMPACT OF ANEMIA ON HOSPITALIZATION COSTS IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE

    May 1, 2008, 00:00

  • PMH47 THE RELATIONSHIP BETWEENTHE ANTIPSYCHOTIC MEDICATION ADHERENCE AND PATIENT OUTCOMES AMONG BIPOLAR DISORDER PATIENTS

    May 1, 2008, 00:00

  • HP3 PRIORITY SETTING FOR NEWTECHNOLOGIES- POSSIBLE DETERMINANTS AMONGTHEWORKING POPULATION

    May 1, 2008, 00:00

  • PCN6 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF TRASTUZUMAB OVER I0YEARS IN 5 EUROPEAN COUNTRIES

    May 1, 2008, 00:00

  • PSS11 A COST-EFFECTIVENESS ANALYSIS OF BRIMONIDINE/TIMOLOL

    May 1, 2008, 00:00

  • DU6 ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2008, 00:00

  • Diabetes-Specific or Generic Measures for Health-Related Quality of Life? Evidence from Psychometric Validation of the D-39 and SF-36

    May 1, 2008, 00:00

  • PCV70 PATIENT ADHERENCE TO CHOLESTEROL TREATMENT (PACT)- CANADIAN PHYSICIAN AND PATIENT PERSPECTIVES

    May 1, 2008, 00:00

  • PHC1 A COST COMPARISON OF CARDIAC SURGERIES BY CHOICE OF FIBRIN SEALANT

    May 1, 2008, 00:00

  • CV4 CANTWO AS RESULT IN A FAILURE?- EFFECT OF ASPIRIN ONTHE RISK OF HEART FAILURE HOSPITALIZATIONS IN CHF PATIENTS ON ACE INHIBITORS

    May 1, 2008, 00:00

  • PHP27 ESTIMATION AND COMPARISON OF ORTHOTIC BRACE COSTS WITH REIMBURSEMENT TARIFFS AND RETAIL PRICES IN BELGIUM

    May 1, 2008, 00:00

  • PND32 DETERMINATION OFTHE LONGITUDINAL VALIDITY AND MINIMALLY IMPORTANT DIFFERENCE OFTHE 8-ITEM PARKINSONS DISEASE QUESTIONNAIRE (PDQ-8)

    May 1, 2008, 00:00

  • PRS18 COST-UTILITY ANALYSIS OF VARENICLINE, AN ORAL SMOKING CESSATION DRUG, IN JAPAN

    May 1, 2008, 00:00

  • AC5 ORAL ANTIDIABETIC MEDICATION ADHERENCE AND HEALTH CARE COSTSAND UTILIZATION AMONG MEDICAID-ENROLLEDTYPE 2 DIABETES PATIENTS NEWLY STARTING MONOTHERAPY

    May 1, 2008, 00:00

  • PDB2 HBAIC GOAL ATTAINMENT IN RELATION TO DOSE AMONG DIABETES PATIENTS USING METFORMIN

    May 1, 2008, 00:00

  • PCN89 DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY

    May 1, 2008, 00:00

  • PCN24 ECONOMIC EVALUATION OF SORAFENIB VERSUS BEST SUPPORTIVE CARE IN ADVANCED RENAL CELL CARCINOMA- AN UPDATED COST-EFFECTIVENESS ANALYSIS

    May 1, 2008, 00:00

  • PMH18 RISK OF NEUROLEPTIC MALIGNANT SYNDROME ASSOCIATED WITH ANTIPSYCHOTICS USE IN PATIENTS WITH BIPOLAR DISORDERS RETROSPECTIVE POPULATION-BASED CASE-CONTROL STUDY

    May 1, 2008, 00:00

  • PCN61 EARLY DISCONTINUATION OF ADJUVANT ENDOCRINE TREATMENT OF BREAST CANCER

    May 1, 2008, 00:00

  • PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS

    May 1, 2008, 00:00

  • PDB60 DISCREPANCIES BETWEEN IMPORTANCE AND EVALUATION OF INSULIN DELIVERY SYSTEM (IDS) FEATURES CONTRIBUTE TO IDS SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • The Impact of Chronic Hepatitis B on Quality of Life- A Multinational Study of Utilities from Infected and Uninfected Persons

    May 1, 2008, 00:00

  • PCV86 PATTERNS OF DIURETIC USE IN MULTI-DRUG ANTI-HYPERTENSIVE REGIMENS IN THE POSTALLHAT ERA

    May 1, 2008, 00:00

  • PHP73 CONSUMPTION PATTERNS AND ECONOMIC BURDEN OF DRUGS IN FORTALEZA, BRAZIL

    May 1, 2008, 00:00

  • DB3 REAL-WORLD ANALYSIS OF PERCENT OF PATIENTS WITH TYPE 2 DIABETES ACHIEVING GLYCEMIC GOAL WITH INSULIN GLARGINE

    May 1, 2008, 00:00

  • PCN20 COST ANALYSIS OF IMMUNOGLOBULIN PROPHYLAXIS IN CHRONIC LYMPHOCYTIC LEUKEMIA

    May 1, 2008, 00:00

  • PHP8 THE EFFECTS OF NONCOMPLIANT COST-CUTTING BEHAVIORS ON INDIRECT COSTS AMONG ADULTS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PCN90 EFFECT OF THE HUNGARIAN ORGANIZED NATIONWIDE CERVICAL CANCER SCREENING PROGRAMME ON THE COVERAGE OF WOMEN UNDER THE AGE OF 25 YEARS

    May 1, 2008, 00:00

  • PHP4 THE IMPACT OF COPAYMENTS OR BRAND NAMED DRUG ON MEDICATION PERSISTENCE

    May 1, 2008, 00:00

  • PCV30 CLOPIDOGREL IS COST-EFFECTIVE COMPARED WITH ASPIRIN IN UNITED KINGDOM PATIENTS WITH A MYOCARDIAL INFARCTION WHO SUBSEQUENTLY SUSTAIN AN ISCHAEMIC STROKE OR PERIPHERAL ARTERIAL DISEASE EVENT

    May 1, 2008, 00:00

  • PIN32 THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF) STUDY-LINKING SURVEY AND CLAIMS DATA TO UNDERSTAND DISEASE IMPACT ON INDIRECT COSTS

    May 1, 2008, 00:00

  • PDB54 DEVELOPMENT OF A CLASSIFICATION SYSTEM FOR A DIABETES-SPECIFIC PREFERENCE-BASED MEASURE OF HEALTH

    May 1, 2008, 00:00

  • PSS36 COMPARISON OF THE QUALITY OF LIFE IMPACT OF PERIPHERAL VISION LOSS VERSUS CENTRAL VISION LOSS

    May 1, 2008, 00:00

  • PGI7 COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE

    May 1, 2008, 00:00

  • PMS34 ATWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTERTOTAL KNEE REPLACEMENT

    May 1, 2008, 00:00

  • PCV22 SIGMOID MAXIMUM EFFECT MODELING OF CORONARY HEART DISEASE DEATH AND MYOCARDIAL INFARCTION RATE VERSUS LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN STATIN SECONDARY PREVENTION TRIALS

    May 1, 2008, 00:00

  • PCN85 EFFECT OF AGE AND PLACE OF RESIDENCE ON COLORECTAL CANCER TREATMENTS IN NEBRASKA CANCER REGISTRY FROM 1998 TO 2003

    May 1, 2008, 00:00

  • PIN3 DATA MINING PHYSICIAN DECISION AND INVESTIGATING TREATMENT OPTIONS OF OSTEOMYELITIS

    May 1, 2008, 00:00

  • PIN39 ROLE OF DRUG DISTRIBUTION STRATEGIES TO IMPROVE HEALTH OUTCOME IN HIGH RISK PATIENTS

    May 1, 2008, 00:00

  • PHC7 COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN POLAND

    May 1, 2008, 00:00

  • PRS8 HEALTH ECONOMICS OF ASTHMAASSESSING THE VALUE OF ASTHMA INTERVENTIONS

    May 1, 2008, 00:00

  • PSY21 THE COST-EFFECTIVENESS OF LYRICA (PREGABALIN) IN PATIENTS WITH CENTRAL NEUROPATHIC PAIN

    May 1, 2008, 00:00

  • PMS2 COMPARATIVE EFFICACY OF BIOLOGICAL TREATMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS; SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

    May 1, 2008, 00:00

  • PCN86 DRUG UTILIZATION AND COST CONSIDERATIONS OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

    May 1, 2008, 00:00

  • PCN46 COMPARISON OF SURGICAL TREATMENT COSTS OF NONMELANOMA SKIN CANCER PATIENTS IN A UNIVERSITY-AFFILIATED PRACTICE

    May 1, 2008, 00:00

  • PDB7 EVALUATION OF INSULIN CONTAINING ANTI-DIABETIC REGIMENS IN HIGH-RISK CARDIOVASCULAR PATIENTS WITH A PRE-TREATMENT AIC MEASUREMENT GREATER THAN 9

    May 1, 2008, 00:00

  • PMC3 METHODS FOR ESTIMATING CONFIDENCE INTERVALS OF PER MEMBER PER MONTH (PMPM) UTILIZATION RATES

    May 1, 2008, 00:00

  • DISCLOSURE INFORMATION

    May 1, 2008, 00:00

  • PGI12 HEALTH CARE COSTS RELATED TO THE TREATMENT OF CROHNS DISEASE

    May 1, 2008, 00:00

  • PSS38 PATIENTS PERCEPTION OF LIFE FREE OF GLASSES AFTER CATARACT SURGERY- DEVELOPMENT OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS)

    May 1, 2008, 00:00

  • PIH17 COST-EFFECTIVENESS OF MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND SURGERY FOR TREATMENT OF UTERINE FIBROIDS

    May 1, 2008, 00:00

  • PSY16 COST-EFFECTIVENESS OFTRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY- A MODEL APPROACH

    May 1, 2008, 00:00

  • PHP82 RECENT TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA

    May 1, 2008, 00:00

  • PMH58 IMPROVEMENT IN PERSONAL AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS TREATED WITH RISPERIDONE LONG ACTING INJECTION)- 6-MONTH RESULTS FROM E-STAR

    May 1, 2008, 00:00

  • Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip

    May 1, 2008, 00:00

  • CV3 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLEEDING DURING CORONARY ARTERY BYPASS GRAFT SURGERY AMONG ELDERLY AMERICANS

    May 1, 2008, 00:00

  • PCN72 DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN BRAZIL- AN ASSESSMENT OF THE CONSTRUCT VALIDITY OF THE HEALTH UTILITIES INDEX (HUI3)

    May 1, 2008, 00:00

  • PMS27 DOES THE FUNDING SOURCE INFLUENCE THE RESULTS IN ECONOMIC EVALUATIONS? A CASE- STUDY IN BISPHOSPHONATES FORTHETREATMENT OF OSTEOPOROSIS

    May 1, 2008, 00:00

  • PRS11 LONG TERM COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS FOR SMOKING CESSATION IN CZECH REPUBLIC

    May 1, 2008, 00:00

  • PM2 WHAT PATIENTS SAYVS. WHAT PATIENTS MEAN- QUALITATIVE RESEARCH IN PRO DEVELOPMENT

    May 1, 2008, 00:00

  • PMC42 METHODOLOGICAL ISSUES WITHTHE ANALYSIS OF PREFERENCE-BASED EQ-5D INDEX SCORE

    May 1, 2008, 00:00

  • PND41 PHYSICIAN AND PATIENT REPORTED OUTCOMES REVEAL RAPID ONSET OF IMPROVEMENT AND OVERALL CONVENIENCE, TOLERABILITY AND EASE-OF-USE WITH RASAGILINE IN PARKINSONS DISEASE (PD) IN LEGATO

    May 1, 2008, 00:00

  • PGI15 ECONOMIC EVALUATION OF PROTON PUMP INHIBITORS, RELATIVE TO ALTERNATIVE GASTROINTESTINAL PROPHYLAXIS AGENTS, FOR PREVENTION OF Gl COMPLICATIONS IN ELDERLY PATIENTS TAKING NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSNSAIDS)

    May 1, 2008, 00:00

  • PMS39 LOSS OF EMPLOYABLE LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS- A PRELIMINARY ANALYSIS USING MARKOV MODEL

    May 1, 2008, 00:00

  • PHP63 SEGMENTED REGRESSION ANALYSIS OF INTERRUPTED TIME SERIES PRESCRIPTION GROSS MARGIN TRENDS FOR INDEPENDENT PHARMACIES BEFORE AND AFTER MEDICARE PART D

    May 1, 2008, 00:00

  • PCV99 THE FIRST MOVER STRIKES AGAIN. COST-EFFECTIVENESS OF STATINS AND PRESCRIBING BEHAVIOR IN PORTUGAL

    May 1, 2008, 00:00

  • PCV21 PREVALENCE, AWARENESS AND MANAGEMENT OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES AMONG UNITED STATES ADULTS AGED 65 AND OLDER

    May 1, 2008, 00:00

  • PMH30 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM OR DIVALPROEX- IN THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

    May 1, 2008, 00:00

  • PHP40 ANALYZING INEQUITY IN HEALTH CARE UTILIZATION BY THE US POPULATION

    May 1, 2008, 00:00

  • PMC32 PREDICTING SF-6D PREFERENCE-BASED UTILITIES USING MEAN SF-36 HEALTH DIMENSION SCORESWHEN PATIENT LEVEL DATA ARE NOT AVAILABLE

    May 1, 2008, 00:00

  • PMS35 QUALITY OF LIFE AMONG OUTPATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL-LIFE SETTING IN GERMANY

    May 1, 2008, 00:00

  • CA4 THE EARLY CLINICAL AND ECONOMIC BENEFITS OF ATORVASTATIN IN A CANADIAN SETTING

    May 1, 2008, 00:00

  • PHP29 STAKEHOLDER PERSPECTIVES ON ECONOMIC EVALUATION- THE CASE OF NICE

    May 1, 2008, 00:00

  • PHP54 PREVALENCE OF CONDITIONS IN THE US EMPLOYER-INSURED POPULATION

    May 1, 2008, 00:00

  • PMH71 PREVALENCE OF CONCOMITANT USE OF ANTICHOLINERGIC MEDICATIONS AND CHOLINESTERASE INHIBITORS IN A MEDICAID NURSING HOME POPULATION

    May 1, 2008, 00:00

  • PUK18 STAFF TIME AND COSTS FOR ANEMIA MANAGEMENT WITH ERYTHROPOIETIC STIMULATING AGENTS IN PATIENTS ON HEMODIALYSIS- CASE STUDY OF A BRAZILIAN DIALYSIS CENTER

    May 1, 2008, 00:00

  • PHP32 WHATS DRIVING PRESCRIPTION COPAYMENTS?

    May 1, 2008, 00:00

  • PMC44 IS A LITERAL BACKTRANSLATION IN PRO DOCUMENTS ALWAYS THE BEST OPTION?

    May 1, 2008, 00:00

  • PMH26 IMPROVED WORK PRODUCTIVITY IN THE UNITED STATES (US) FOR PATIENTS TREATED WITH ESCITALOPRAM COMPARED TO DULOXETINE

    May 1, 2008, 00:00

  • DU7 NATIONAL ESTIMATES AND DETERMINANTS OF DEPRESSION AND ANTIDEPRESSANTTREATMENT IN CANCER PATIENTS IN THE UNITED STATES, 2004-2005

    May 1, 2008, 00:00

  • PMS21 THE RELATIONSHIP BETWEEN COST OF ILLNESS AND DISEASE SEVERITY IN RHEUMATOID ARTHRITIS- RESULTS OF A SYSTEMATIC REVIEW

    May 1, 2008, 00:00

  • PCV75 LOW-DENSITY LIPOPROTEIN APHERESIS FORTHE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA

    May 1, 2008, 00:00

  • PIH5 THE EFFECT OF INJURY SEVERITY ON THE INCIDENCE AND RESOURCE UTILIZATION-RELATED OUTCOMES OF DEEP VEIN THROMBOSIS AMONG PEDIATRIC TRAUMA ADMISSIONS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PCN30 COSTS RELATED TO ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS IN CANADA

    May 1, 2008, 00:00

  • CA1 ECONOMIC ANALYSIS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS INTHE PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH-A CANADIAN PERSPECTIVE

    May 1, 2008, 00:00

  • PRS9 THE COST-EFFECTIVENESS OF TARGETED PRESCRIBING OF ANTIMICROBIALS IN CANADA FOR COMMUNITY-ACQUIRED PNEUMONIA IN AN ERA OF ANTIMICROBIAL RESISTANCE

    May 1, 2008, 00:00

  • PCN19 A COST-EFFECTIVENESS ANALYSIS OF LAPATINIB AT A TERTIARY CANCER CENTER

    May 1, 2008, 00:00

  • Cost-Effectiveness of Intraperitoneal Chemohyperthermia in the Treatment of Peritoneal Carcinomatosis from Colorectal Cancer

    May 1, 2008, 00:00

  • PRS47 ASTHMA PHARMACOTHERAPYAND AT RISK NON-AFRICAN AMERICAN MINORITY POPULATIONS- EVIDENCE OF SUB-OPTIMAL CARE FROM THE NATIONAL AMBULATORY MEDICAL SURVEY 1998-2004

    May 1, 2008, 00:00

  • MH2 ECONOMIC AND CLINICAL CONSEQUENCES ASSOCIATED WITH POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ANTIPSYCHOTICS AND CONCOMITANT MEDICATIONS IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PCV58 MODELING CARDIOVASCULAR HEALTH OUTCOMES IN MEDICAID HYPERTENSIVE PATIENTS-EFFECT OF PATIENT ADHERENCE

    May 1, 2008, 00:00

  • HP4 25YEARS OFTHE ORPHAN DRUG ACT-ANALYSIS OFTHE NEW ORPHAN DRUGSAPPROVED BETWEEN 1983 AND 2007

    May 1, 2008, 00:00

  • PSY32 COST-UTILITY STUDY OF RECOMBINANT FACTORVIII IN THE TREATMENT OF HEMOPHILIA A IN MEXICO

    May 1, 2008, 00:00

  • PDB61 PREDICTORS OF INSULIN DELIVERY SYSTEM USE IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2008, 00:00

  • PIN43 NATURAL HISTORY OF CHRONIC HCV INFECTION OBTAINED THROUGH INJECTION DRUG USE- A BAYESIAN META-ANALYSIS

    May 1, 2008, 00:00

  • PCV24 ASSESSMENT OF SAFETY FOR BROMOCRIPTINE- COMPARISONS OF REPORTING SYSTEMS AND A RETROSPECTIVE COHORT STUDY

    May 1, 2008, 00:00

  • PND40 PHYSICAL AND PATIENT REPORTED OUTCOMES IN MULTIPLE SCLEROSIS

    May 1, 2008, 00:00

  • PHP60 DEVELOPMENT OF A DRUG INVENTORY MANAGEMENT MODEL FOR THE STATE HOUSE MEDICAL CENTRE, ABUJA, NIGERIA

    May 1, 2008, 00:00

  • PIH6 ECONOMIC ASSESSMENT OF SILDAFENIL FOR THE MANAGEMENT OF PATIENTS WITH ERECTILE DYSFUNCTION (ED) SECONDARYTO DIABETES MELLITUSTYPE 2 (DM2) AND HYPERTENSION IN MEXICO

    May 1, 2008, 00:00

  • OM2 USINGVALUE OF INFORMATION METHODOLOGYTO DETERMINE THE SAMPLE SIZE FOR A RANDOMIZED CLINICAL TRIAL FROM AN INDUSTRY PERSPECTIVE

    May 1, 2008, 00:00

  • PCV9 TRENDS IN MORTALITY, LENGTH OF STAY AND READMISSIONS AMONG PATIENTS WITH ACUTE STROKE AT THE NATIONAL HEALTHCARE GROUP, SINGAPORE, 2000-2006

    May 1, 2008, 00:00

  • PCV14 EVALUATION OF RESISTANT HYPERTENSION IN A USUAL-CARE SETTING

    May 1, 2008, 00:00

  • PDB11 PREVALENCE OF AND RISK FACTORS FOR HOSPITALIZATIONS IN PATIENTS WITH TYPE 2 DIABETES IN SOUTH KOREA

    May 1, 2008, 00:00

  • MH3 WORK ABSENTEEISMAND BED DAYS IN CHRONIC MEDICAL DISORDER PATIENTS WITH AND WITHOUT DEPRESSION IN THE UNITED STATES, 2004-2005

    May 1, 2008, 00:00

  • PMH79 PHYSICAL MORBIDITY AMONG PATIENTS WITH SCHIZOPHRENIA- ANALYSIS OFTHE NATIONAL HOSPITAL DISCHARGE REGISTRY

    May 1, 2008, 00:00

  • PCV77 ASSESSMENT OF CONTROL AND TREATMENT PATTERNS IN AN ELDERLY POPULATION WITH COMORBID DIABETES AND HYPERTENSION

    May 1, 2008, 00:00

  • PCN2 SYSTEMATIC REVIEW OF PALONOSETRON IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

    May 1, 2008, 00:00

  • PHP53 TRENDS IN COMMUNITY BASED ADVERSE DRUG EVENTS IN THE UNITED STATES- 1996-2005

    May 1, 2008, 00:00

  • PCN3 EFFECTIVENESS OF BORTEZOMIB IN MULTIPLE MYELOMA- PRELIMINARY RESULTS FROM AN INTERNATIONAL ELECTRONIC OBSERVATIONAL STUDY

    May 1, 2008, 00:00

  • PSS37 MAPPING THE DERMATOLOGY QUALITY OF LIFE INDEX (DLQI)TO HEALTH-RELATED UTILITYVIATHE SF-12 IN SUBJECTS WITH ECZEMA

    May 1, 2008, 00:00

  • PSY7 BURDEN OF OBESITY- 10-YEAR REVIEW OF PUBLISHED LITERATURE ON OBESITY PREVALENCE IN NINE COUNTRIES

    May 1, 2008, 00:00

  • Literature Review of Methods to Translate Health-Related Quality of Life Questionnaires for Use in Multinational Clinical Trials

    May 1, 2008, 00:00

  • PSS22 THE ANNUAL COST OF BACTERIAL CONJUNCTIVITIS IN THE UNITED STATES- EVIDENCE FROM AN ECONOMIC MODELLING APPROACH

    May 1, 2008, 00:00

  • PMH7 CLINICAL AND FUNCTIONAL IMPROVEMENTS IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH RISPERIDONE LONG ACTING INJECTION- INTERIM RESULTS FROM OBSERVATIONAL STUDIES CONDUCTED IN AUSTRALIA, BELGIUM AND THE UNITED STATES

    May 1, 2008, 00:00

  • PGI22 VALIDATION OF A NOCTURNAL GASTROESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOM SEVERITY AND IMPACT INSTRUMENT

    May 1, 2008, 00:00

  • DU8 THE EFFECT OFTHREE-TIER FORMULARY ADOPTION FOR ALPHA-BLOCKERS ON DRUG UTILIZATION INTHE DEPARTMENT OF DEFENSE

    May 1, 2008, 00:00

  • MD4 IMPACT OF THE MEDICARE MODERNIZATION ACT OF 2003 ON PART B DRUG USE AND SPENDING- A CASE STUDY OF BIOLOGICALS FOR RHEUMATOID ARTHRITIS

    May 1, 2008, 00:00

  • PCN48 LONGITUDINAL COMPARISON ACROSS TREATMENTS, RISK AND AGE OF WORK LOSS COSTS IN PROSTATE CANCER PATIENTS- 10 YEAR PATTERNS

    May 1, 2008, 00:00

  • PMH5 REHOSPITALIZATION AFTER DISCONTINUATION OF PALIPERIDONE ER IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2008, 00:00

  • PHP11 ETHNIC DISPARITIES IN HOSPITAL DISCHARGES AGAINST MEDICAL ADVICE AMONG CARDIOVASCULAR DISEASE PATIENTS-THE ROLE OF HOSPITAL QUALITY

    May 1, 2008, 00:00

  • PCV33 LONG-TERM REDUCTION OF CARDIOVASCULAR EVENTS AND COST-EFFECTIVENESS OF DIFFERENT STATINS AND DOSES IN MEXICO

    May 1, 2008, 00:00

  • PHP35 CHARACTERIZING PHARMACY AND MEDICAL CLAIMS FOR A PRIVATE INSURANCE POLYPHARMACY POPULATION

    May 1, 2008, 00:00

  • PIN36 BASELINE CHARACTERISTICS ASSOCIATED WITH HOSPITAL LENGTH OF STAY (LOS) FOR PATIENTS WITH STAPHYLOCOCCUSAUREUS SKIN INFECTIONS IN THE 1996-2005 NATIONAL HOSPITAL DISCHARGE SURVEY (NHDS)

    May 1, 2008, 00:00

  • PCN39 DIFFERENCES IN COLORECTAL CANCER TREATMENT COSTS BYTREATMENT PHASE, CANCER SITE, AND STAGE AT DIAGNOSIS- EVIDENCE FROM LINKED SEER-MEDICARE DATA

    May 1, 2008, 00:00

  • PHC11 A SYSTEMATIC REVIEW OF STUDIES ON QUALITY OF LIFE IN ANIMALS

    May 1, 2008, 00:00

  • PHP16 IMPROVING HEALTH TECHNOLOGY APPRAISAL AND DECISION-MAKING- WHAT HAS THE BRITISH PARLIAMENTS INQUIRY OF NICE TAUGHT US?

    May 1, 2008, 00:00

  • PRS34 NICOTINE REPLACEMENT THERAPY AND THE MAINE TOBACCO HELPLINE- KNOWLEDGE, UTILIZATION PATTERNS, SHORT-TERM OUTCOMES. AND SATISFACTION AMONG SMOKERS

    May 1, 2008, 00:00

  • PND46 THE RISKS OF MULTIPLE GENERIC SUBSTITUTION OF ANTIEPILEPTIC DRUGS- THE CASE OFTOPIRAMATE

    May 1, 2008, 00:00

  • CN2 ECONOMIC EVALUATION OF EGFR-GUIDEDTREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER

    May 1, 2008, 00:00

  • IN3 A MICROSIMULATION OF THE COST-EFFECTIVENESS OF MARAVIROC FORANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS

    May 1, 2008, 00:00

  • PCN33 COST UTILITY ANALYSIS OF VACCINATION AGAINST HPV IN ISRAEL

    May 1, 2008, 00:00

  • PIH21 LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS TO ASSESS WOMENS PREFERENCES AND WILLINGNESS TO PAY FOR MATERNAL HEALTH SERVICES

    May 1, 2008, 00:00

  • PHP6 PREDICTORS OF NONCOMPLIANT COST-CUTTING BEHAVIORS AMONG ADULTS IN THE UNITED STATES

    May 1, 2008, 00:00

  • PIH1 PREVENTION OF FALLS AND FALL-RELATED INJURIES IN THE COMMUNITY-DWELLING ELDERLYA REVIEW

    May 1, 2008, 00:00

  • PIN14 COST-EFFECTIVENESS OF PEGINTERFERON-ALFA-2A (40 KD) ASSOCIATED WITH RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C IN BRAZIL UNDER THE PRIVATE HEALTH CARE SYSTEM

    May 1, 2008, 00:00

  • IN1 C. ALBICANS AND C. GLABRATA BLOODSTREAM INFECTIONS IN ADULTS- OUTCOMES AND ASSOCIATED COSTS

    May 1, 2008, 00:00

  • PMC20 METHODSTO SUMMARIZE COMPLICATED DATASETS CONTAINING STRUCTURED, NOMINAL DATA USING SAS

    May 1, 2008, 00:00

  • PSS31 ASSESSMENT OF QUALITY OF LIFE IN DAILY CLINICAL DERMATOLOGICAL ROUTINE- QUESTIONNAIRES AND CHECKLIST

    May 1, 2008, 00:00

  • PCN69 QUALITY OF LIFE IMPACT OF HOT FLUSHES IN MEN RECEIVING TREATMENT FOR PROSTATE CANCER

    May 1, 2008, 00:00

  • PSS12 COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB AND RANIBIZUMAB IN NEOVASCULARAGE-RELATED MACULAR DEGENERATION (AMD)- A CLINICAL AND ECONOMIC COMPARISON OF TWO VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR TREATMENTS

    May 1, 2008, 00:00

  • PMH32 ACAMPROSATE IN TREATMENT OF ALCOHOL DEPENDENCE-ECONOMIC BENEFITS REVISITED

    May 1, 2008, 00:00

  • PCN81 INJECTABLE CHEMOTHERAPYVS CAPECITABINE- PREFERENCE IN BRAZILIAN PATIENTS

    May 1, 2008, 00:00

  • PSS24 TRENDS IN EPISODE OF TREATMENT COSTS OF ACNE ACROSS THE UNITED STATES

    May 1, 2008, 00:00

  • PHP51 COMPARISONS OF RELATIVE RISKS OF SERIOUS COMORBIDITIES AMONG EMPLOYEES WITH AND WITHOUT INSOMNIA, GERD, HEPATITIS C, MULTIPLE SCLEROSIS, AND CHRONIC CONSTIPATION

    May 1, 2008, 00:00

  • PIN51 A PICTURE OF DEMOGRAPHIC DISPARITIES IN THE RECEIPT OF ANTIRETROVIRAL THERAPY AMONG HIV PATIENTS IN THE 2000-2005 NATIONAL AMBULATORY MEDICAL CARE SURVEYS (NAMCS)

    May 1, 2008, 00:00

  • PHP75 SATISFACTION WITH MEDICATION- PRELIMINARY RESULTS FROM A NOVEL PATIENT REGISTRYTRACKING SATISFACTION WITH DIFFERENT CHRONIC MEDICATIONS

    May 1, 2008, 00:00

  • PDB5 COMPARISON OF CLINICAL EFFECTIVENESS AND SAFETY OF GLULISINE VERSUS INSULIN LISPRO, ASPART AND REGULAR HUMAN INSULIN IN PATIENTS WITH TYPE I AND 2 DIABETES

    May 1, 2008, 00:00

  • PCV44 RELATIONSHIP BETWEEN THE OBESITY PARADOX AND HEALTH CARE EXPENDITURES IN SUBJECTS WITH CARDIOVASCULAR DISEASE USING THE MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2008, 00:00

  • PMS15 COST-EFFECTIVENESS OF THE TREATMENT FOR EARLY RHEUMATOID ARTHRITIS IN MEXICO- INFLIXIMAB VS. ADALIMUMAB

    May 1, 2008, 00:00

  • PSY54 DEVELOPMENT OF AN OPIOID ROTATION MODEL

    May 1, 2008, 00:00

  • PCN83 KNOWLEDGE OF THE BRAZILIAN POPULATION ABOUT COLORECTAL CANCER

    May 1, 2008, 00:00

  • PHP26 RESEARCH AND MARKETING COMPLEMENTARITY IN PHARMACEUTICAL FIRMS- EMPIRICAL EVIDENCE

    May 1, 2008, 00:00

  • PCV90 DISPARITIES IN MEDICAL EXPENDITURES AND UTILIZATION AMONG HYPERTENSIVE MEN AND WOMEN IN THE UNITED STATES

    May 1, 2008, 00:00

  • PCN93 THREE SCIENTIFIC PARADIGMS IN HEALTH TECHNOLOGY ASSESSMENT- EXPERIENCES OF THE COMMITTEE TO EVALUATE DRUGS IN ONTARIO, CANADA

    May 1, 2008, 00:00

  • MD7 DIFFERENTIALTAKE-UP OFTHE MEDICARE PART D PRESCRIPTION DRUG BENEFIT

    May 1, 2008, 00:00

  • PCN94 PREDICTORS OF TREATMENT CHOICE IN HIGH RISK AND METASTATIC MELANOMA- EVIDENCE FROM LINKED ELECTRONIC MEDICAL RECORDS AND ADMINISTRATIVE CLAIMS DATA

    May 1, 2008, 00:00

  • PSY26 THE DIRECT MEDICAL COSTS ASSOCIATED WITH SUSPECTED (CONFIRMED AND NEGATIVE) HEPARIN-INDUCEDTHROMBOCYTOPENIA

    May 1, 2008, 00:00

  • PMS43 CHARACTERISTICS OF PHARMACEUTICS HAVING NO ALTERNATIVES

    May 1, 2008, 00:00

  • PDB57 CONTENT DEVELOPMENT FORA NEW INSTRUMENT TO ASSESS PATIENT AND PARENT PREFERENCE FOR GROWTH HORMONE REPLACEMENT THERAPY DELIVERY DEVICES

    May 1, 2008, 00:00

  • PCN55 A COST-UTILITY ANALYSIS OF FULVESTRANT IN TREATING RECURRENT METASTATIC BREAST CANCER

    May 1, 2008, 00:00

  • PSS10 COST-EFFECTIVENESS OF ANTIVEGF THERAPIES FOR WET AGE-RELATED MACULAR DEGENERATION-AMD IN BRAZIL- THE PRIVATE PAYER PERSPECTIVE

    May 1, 2008, 00:00

  • DU4 PRESCRIPTION DRUG UTILIZATION AMONG A NATIONALLY REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES WITH HEART FAILURE

    May 1, 2008, 00:00

  • PCASE1 GCSF- SAVING COSTS WITHOUT SAVING QUALITY OF CARE. A UNIMED VITORIA HEALTH INSURANCE EXPERIENCE

    May 1, 2008, 00:00

  • PDB24 LONG-TERM CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN DETEMIR PLUS INSULIN ASPART IN TYPE I DIABETES PATIENTS IN THE CZECH SETTING; DATA FROM THE PREDICTIVE STUDY

    May 1, 2008, 00:00

  • PMH67 CLINICAL CHARACTERISTICS AMONG ANTIDEPRESSANT INITIATORS

    May 1, 2008, 00:00

  • PSY30 EVALUATION OF COST AND OUTCOMES OF WEIGHT CONTROL PROGRAM IN A REGIONAL HOSPITAL AT SOUTHERNTAIWAN

    May 1, 2008, 00:00

  • PUK22 ASSESSING PATIENT DESCRIPTIONS OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND PERSPECTIVES ON TREATMENT OUTCOMES FOR THE DEVELOPMENT OF A NEW LUTS PATIENT REPORTED OUTCOME TOOL

    May 1, 2008, 00:00

  • PDB27 THE COST-EFFECTIVENESS OF INSULIN GLULISINE IN TYPE 2 DIABETES IN POLAND

    May 1, 2008, 00:00

  • PMS20 THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS- AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

    May 1, 2008, 00:00

  • PND4 TRENDS AMONG HOSPITALIZED CYSTIC FIBROSIS PATIENTS

    May 1, 2008, 00:00

  • AC1 THEASSOCIATION BETWEEN IMPROVEMENTS IN DRUG ADHERENCE AND SHORT-TERM SERVICE UTILIZATION AND COSTS IN A MEDICAID POPULATION

    May 1, 2008, 00:00

  • PCN52 DIRECT MEDICAL COST OF BREAST CANCER BY STAGE OF CLINICAL DISEASE. A MEXICAN COHORT

    May 1, 2008, 00:00

  • PND5 SUBSTANCE ABUSE AMONG PATIENTS DIAGNOSED WITH INSOMNIA

    May 1, 2008, 00:00

  • PMS17 LONGITUDINAL ESTIMATES AND COST-EFFECTIVENESS ANALYSIS OF ANTI-RESORPTIVE AGENTS FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRACTURES BASED ON US NATIONAL SURVEYS

    May 1, 2008, 00:00

  • PND6 MODELING THE IMPACT OF A FIXED-DOSE COMBINATION OF SUMATRIPTAN AND NAPROXEN SODIUM ONTRIPTAN CONSUMPTION IN A US MANAGED CARE POPULATION

    May 1, 2008, 00:00

  • PCASE4 HEALTH PLAN AND INDUSTRY- NEW PARTNERSHIP TO ASSESS NEW TECHNOLOGY OUTCOMES AND ECONOMIC IMPACT

    May 1, 2008, 00:00

  • PIH14 ECONOMIC EVALUATION OF ATOSIBAN VERSUS BETA-MIMETICS IN THE TREATMENT OF PRETERM LABOUR IN GERMANY

    May 1, 2008, 00:00

  • PSS1 CO-MORBIDITIES INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS

    May 1, 2008, 00:00
  • «
  • 151 (current)
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • »